Riskpilot← Back to searchSign inGet full accessCorsmed AB
ABActiveOrg 5590931779Birger Jarlsgatan 57 CResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20165-9 employees
Revenue 2024
SEK 15,7M
+55% vs 2023
EBITDA margin
-26.0%
+68% vs 2023
Equity ratio
74.4%
Financial strength
Net profit 2024
SEK -5,6M
+62% vs 2023
| Revenue | SEK 15,7M | +55% |
| EBITDA | SEK -4,1M | +68% |
| Net profit | SEK -5,6M | +62% |
| Total assets | SEK 64,3M | +109% |
| Equity | SEK 47,8M | +246% |
| Employees | — | — |
Legal name
Corsmed AB
Org number
5590931779
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
21 december 2016
Share capital
SEK 126 000
Employees
5-9
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva utveckling, internationell marknadsföring och försäljning av licenser och produkter inom området medicinsk teknik samt idka därmed förenlig verksamhet.
Address
Birger Jarlsgatan 57 C
Email
erik.jacobsson@corsmed.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 11 | 831 | 3 055 | 8 583 | 10 133 | 15 746 |
| Staff expenses | — | — | — | — | — | — | — | — |
| EBITDA | −33 | −85 | −373 | −1 201 | −6 833 | −19 426 | −12 829 | −4 097 |
| Depreciation & amort. | −0 | −0 | −0 | −74 | −450 | −1 081 | −1 081 | −1 081 |
| EBIT | −33 | −85 | −373 | −1 275 | −7 283 | −20 507 | −13 910 | −5 178 |
| Net financials | — | — | — | −29 | −51 | −29 | −711 | −401 |
| Profit before tax | −33 | −85 | −373 | −1 304 | −7 334 | −20 536 | −14 621 | −5 579 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −33 | −85 | −373 | −1 304 | −7 334 | −20 536 | −14 621 | −5 579 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 235 | 165 | 2 427 | 10 064 | 35 867 | 24 215 | 30 742 | 64 318 |
| Equity | 217 | 147 | 2 107 | 863 | 22 479 | 9 517 | 13 848 | 47 845 |
| Long-term debt | 0 | 0 | 0 | 69 | 2 009 | 1 709 | 5 229 | 3 549 |
| Short-term debt | 18 | 18 | 320 | 9 131 | 11 378 | 12 988 | 11 665 | 12 924 |
| Total debt | 18 | 18 | 320 | 9 200 | 13 387 | 14 697 | 16 894 | 16 473 |
EBITDA margin
-26.0%
This company
15.8%
Market median
-265% vs market
20172024
Equity ratio
74.4%
This company
38.2%
Market median
+95% vs market
20172024
Return on equity
-11.7%
This company
18.4%
Market median
-164% vs market
20172024
Net profit margin
-35.4%
This company
8.1%
Market median
-537% vs market
20172024
Asset turnover
0.24×
This company
1.12×
Market median
-79% vs market
20172024
Debt / equity
0.34×
This company
0.62×
Market median
+45% vs market
20172024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-12-01 – 2017-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TM Chief Auditor | Chief Auditor | 2022 | — | — |
KO Chief Auditor | Chief Auditor | 2021 | — | — |
MS Chief Auditor | Chief Auditor | 2020 | — | — |
PE Chief Auditor | Chief Auditor | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2026 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Corsmed AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tony Mikael Salonen | Chief Auditor | 0 companies |
| Karl Olof Andersson | Chief Auditor | 0 companies |
| Maria Sofia Ekelund | Chief Auditor | 0 companies |
| Peter Emanuel Hamberg | Chief Auditor | 0 companies |
| Tomas Kramar | Board of Directors | 0 companies |
| Nikolaos Kalliagkopoukos | Board of Directors | 0 companies |
| Magdalena Eva Lukaszewicz | Board of Directors | 0 companies |
| Sven Erik Hedström | Board of Directors | 0 companies |
| Anthony Aletras | Board of Directors | 0 companies |
| Karl Stefan Tell | Board of Directors | 0 companies |
| Carl Magnus Bergman | Board of Directors | 0 companies |
| Johan Mårten Öbrink | Chairman | 0 companies |
| John Erik Olof Larsson | Board of Directors | 0 companies |
| Christos Xanthis | Board of Directors | 0 companies |
| Daniel Teodor Wisenhoff | Board of Directors | 0 companies |
| Erik Gustav Staffan Jacobsson | Chairman | 0 companies |